Nolpaza (Pantoprazole)

Pantoprazole is a proton pump inhibitor used to manage disorders associated with excessive gastric acid production.

• Gastroesophageal reflux disease: lowers acid exposure and improves heartburn and regurgitation symptoms.
• Erosive esophagitis: promotes healing of acid‑related esophageal lesions.
• Peptic ulcer disease: supports ulcer healing and prevents recurrence.
• Stress ulcer prophylaxis: reduces the risk of stress‑related gastric bleeding in critically ill patients.

• Pantoprazole irreversibly binds to the H+/K+ ATPase enzyme (gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly suppresses gastric acid secretion, leading to increased gastric pH and reduced acid‑related injury.

Pantoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: watery stools without blood.
• Nausea: occasional upset stomach.
• Abdominal pain: cramping or discomfort.
• Flatulence: increased gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Clostridioides difficile infection: persistent diarrhea with possible colitis.
• Elevated liver enzymes: signs of hepatic stress.
• Thrombocytopenia: low platelet count leading to easy bruising.
• Stevens‑Johnson syndrome: severe skin blistering.
• Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

When using intravenous pantoprazole, clinicians should consider several safety measures.

• Assess renal function: adjust therapy in severe impairment.
• Monitor electrolytes: risk of hypomagnesemia with prolonged use.
• Use with caution in hepatic disease: limited data on safety.
• Avoid in known hypersensitivity to pantoprazole or other PPIs.
• Pregnancy and lactation: safety not established; weigh benefits against risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Rilpivirine: reduced absorption leading to loss of antiviral effect.
• Clopidogrel: possible reduction of antiplatelet activity.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase INR and bleeding risk.
• Digoxin: potential rise in serum digoxin levels.
• Methotrexate: increased toxicity due to reduced clearance.
• Atorvastatin: modest increase in statin exposure.